Acquisition by private equity group Genstar Capital would allow eResearch Technologies (ERT) a more flexible approach and reduce costs according to CEO Jeff Litwin.
INC Research says the closure of former Kendle office in Connecticut will better balance resources and that – where possible – staff will be reassigned.
Contract services firm Warnex says its analytical and bioanalytical divisions have attracted ‘interest’ from buyers that would exceed its current market cap.
New research suggests that – in general - strategic partnerships are working but CROs still need to improve on sponsors’ ‘high priority’ objectives or risk losing deals.
Sourcing comparator drugs for trials is a complex ‘art’ that requires knowledge of trading, regional regulations and an awareness of drugmakers’ competitive concerns according to Clinigen Group CEO Peter George.
Formac Pharmaceuticals and WR Grace say their silica platform can improve the formulation selection process for poorly soluble APIs (active pharmaceutical ingredients).
Quintiles’ CEO says CROs need to evolve with Pharmas, take opportunities in emerging markets and help customers demonstrate value to a growing number of stakeholders.
The head of Pfizer's virtual clinical trial has defended the project after its initial failure to recruit patients raised questions about its viability.
More evidence Russia’s Ministry of Health (MoH) may be getting better at approving trials emerged this week - at least when it comes to international studies.
